Mutual Advisors LLC Decreases Stake in Amgen Inc. (NASDAQ:AMGN)

Mutual Advisors LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,334 shares of the medical research company’s stock after selling 1,882 shares during the period. Mutual Advisors LLC’s holdings in Amgen were worth $4,132,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC purchased a new stake in Amgen in the third quarter worth approximately $29,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the 2nd quarter worth approximately $30,000. Matrix Trust Co purchased a new stake in Amgen during the 3rd quarter valued at $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the 3rd quarter valued at $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 1.6 %

Shares of Amgen stock opened at $277.88 on Friday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The business has a 50-day moving average price of $271.91 and a 200-day moving average price of $306.43. The firm has a market cap of $149.37 billion, a price-to-earnings ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.96 EPS. Equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.43%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 115.24%.

Analysts Set New Price Targets

AMGN has been the subject of several research analyst reports. Wolfe Research initiated coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Finally, UBS Group decreased their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.